XLIFE-SCIENCES-AG
Xlife Sciences AG and Solothurn-based anfass Life Technologies AG have entered a joint venture. Hence, the jointly founded Quadira Biosciences AG has access to the 3D CoSeedis(TM) technology platform of abc biopply ag. This unique 3D cell technology enables the replication of human tissue for reliable testing and characterization of antibodies without animal testing. Xlife's technology platform for the development of antibodies will be used even more efficiently.
As of today, Xlife Sciences AG has already identified 30 compounds with blockbuster potential with its antibody screening platform. These therapeutic antibodies have already shown to be safe and effective in humans. Xlife can modify these antibodies with utmost accuracy and increase the quality of the active ingredient. These are mainly advanced, highly potent antibodies with higher cytotoxic activity and improved side effect profile for cancer therapy. The target market potential of the pre-selected antibodies is in the range of several billion US dollars.
With the collaboration of abc biopply, a portfolio company of anfass Life Technologies, the development process will be advanced significantly. Abc biopply developed a technology platform 3D CoSeedis(TM) that allows the testing and characterization in terms of efficacy of antibodies in 3D- cell cultures, also known as organoids, which are similar to animal or human tissue. This reduces or even eliminates animal testing and accelerates product development significantly. 3D CoSeedis(TM) differentiates itself with its unique homogeneity of produced spheroids and allows standardized mass production. This leads to simplified preclinical modelling of diseases. With this sustainable joint-venture, Quadira Biosciences AG could revolutionize cancer therapy.
About anfass Life Technologies AG
anfass Life Technologies AG invests in promising technologies in the fields of biotech, medical technology and diagnostics. The company also provides strategic and operational support to start-ups and SMEs in the life science sector and offers access to a broad expertise and a reliable network of selected partners. www.anfass.ch
abc biopply ag is a portfolio company of anfass Life Technologies AG. www.biopply.com
.
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
IMPORTANT NOTE: The Annual General Meeting of Xlife Sciences AG will now take place on May 11, 2021, due to the Covid-19 measures of the federal government in written form by letter.
Language: |
English |
Company: |
Xlife Sciences AG Klausstrasse 19 8008 Zürich Switzerland |
Phone: |
0041 44 385 84 60 |
E-mail: |
|
Internet: |
|
ISIN: |
CH0461929603 |
WKN: |
A2PK6Z |
Listed: |
Regulated Unofficial Market in Frankfurt, Munich EQS |
News ID: |
1173329 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210304006227/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agendia to Present FLEX Study Data on Impact of BluePrint® at ESMO Breast Cancer 20256.5.2025 08:00:00 CEST | Press release
Real-world analysis shows BluePrint® identifies chemotherapy-sensitive Basal-type tumors among MammaPrint® High Risk HR+ HER2- breast cancers, supporting more personalized treatment strategies Agendia®, Inc., today announced that new data from its ongoing FLEX Study will be presented at the upcoming ESMO BreastCancer 2025 congress taking place May 14-17 in both Munich, Germany and virtually. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505212759/en/ The FLEX Study (NCT03053193) is a prospective real-world evidence, observational breast cancer study designed to correlate whole transcriptome gene expression in early-stage breast cancer with clinical outcomes, and to evaluate how genomic insights can inform treatment decisions in early-stage breast cancer. In this analysis, researchers examined the impact of BluePrint, Agendia’s 80-gene molecular subtyping assay, on pathological complete response (pCR) rates and chemothera
Owkin Launches K Navigator, a Ground-breaking Agentic Co-pilot to Speed up Breakthroughs in Biomedical Research by 20x6.5.2025 06:15:00 CEST | Press release
K Navigator increases researcher productivity by 20x¹, accelerating biomedical breakthroughs and outperforming leading generalist LLMs Analyzes and visualizes multimodal patient data, plus exclusive access to MOSAIC Window, a subset of the world’s largest spatial omics dataset in oncology Built by biologists, for biologists. Free to use for academic researchers.² Owkin, a leading agentic AI company, has launched K Navigator, an AI-powered research co-pilot designed to revolutionize biomedical science. K Navigator is an agentic playground where researchers can explore, refine, and validate hypotheses, accelerating the quality and pace of their discoveries. With K Navigator, Owkin moves closer to its vision of developing the world’s first Biological Artificial Superintelligence (BASI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505282917/en/ K Navigator home screen. A single natural language interface - K Navigator enab
NIKE, Inc. Announces Senior Leadership Changes to Accelerate Growth and Drive Win Now Action Plan5.5.2025 22:15:00 CEST | Press release
Amy Montagne Becomes President, NikePhil McCartney Becomes EVP, Chief Innovation, Design & Product OfficerNicole Graham Becomes EVP, Chief Marketing OfficerTom Clarke Becomes Chief Growth Initiatives OfficerHeidi O’Neill to Retire NIKE, Inc. (NYSE:NKE) announced a series of strategic changes to its Senior Leadership Team (SLT), elevating experienced leaders to accelerate progress against its Win Now action plan to position the company for future growth. Elliott Hill, President and CEO, NIKE, Inc. and Heidi O’Neill, President of Consumer, Product, and Brand, have decided the Consumer, Product, and Brand leadership will now be divided into three distinct areas: Consumer and Sport, Marketing, and Product Creation, inclusive of Innovation and Design. These roles will now report directly to Hill. As a result of these changes O’Neill has decided to retire from Nike after 26 years. She will continue to serve in an advisory capacity until September 2025. “For nearly three decades, Heidi has be
LR Health & Beauty Once Again Demonstrates Its Expertise in Aloe Vera5.5.2025 16:24:00 CEST | Press release
The social commerce company develops a unique combination of Aloe Vera Gel and fermented Aloe LR Health & Beauty has been synonymous with the best Aloe Vera quality on the market for over 20 years, and continuously invests in new product innovations to take full advantage of the plant's range of beneficial properties. The majority of the over 60 products are developed and produced directly at the company headquarters in Ahlen. LR has now made a decisive breakthrough in skin care cosmetics with its unique combination of pure Aloe Vera leaf gel and fermented Aloe Vera. The care products with the highest Aloe Vera content therefore not only work in the upper and middle layers of the skin, but also unleash the full potential of Aloe Vera in the deeper layers. The effectiveness of this LR Aloe Via Magic Power Duo has been confirmed by the dermatological institute, Dermatest. All the products tested based on a combination of Aloe Vera Gel and fermented Aloe were awarded the 5-star "very good
MultiBank Group Signs Strategic Partnership With MAG to Tokenize $3 Billion Real Estate Assets5.5.2025 16:09:00 CEST | Press release
The largest tokenization initiative of its kind comes ahead of the $MBG token launch, paving the way for regulated digital access to prime property assets MultiBank Group, the world’s largest financial derivatives institution based in Dubai has signed a historic $3 billion tokenization agreement with MAG, the leading real estate developer in the UAE, and Mavryk, a leading blockchain innovator — marking the largest real-world asset (RWA) tokenization initiative globally to date. The initiative highlights the imminent launch of $MBG, the utility token at the core of MultiBank’s next-generation digital finance ecosystem. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505317631/en/ MultiBank Group Signs Strategic Partnership With MAG to Tokenize $3 Billion Real Estate Assets The partnership will bring MAG’s high-value real estate developments — The Ritz-Carlton Residences, Dubai, Creekside, which is part of the Keturah Resort
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom